Rheumnow Podcast

SGLT2 Inhibitors in Lupus Nephritis Not Seronegative Rheumatoid Arthritis-Interstitial Lung Disease Anti-CCP Antibody Testing on the Spot Lessons learned from ReBioLup data in Lupus Nephritis

RA-ILD and Lung Cancer Good News and Bad News for CCP+ at Risk for RA Sex Differences in Psoriatic Arthritis Drugs in Lupus Nephritis Save Kidney Function, Increase Survival What Happens to Muscle Mass and Muscle Strength in RA GLP-1 Agonists in Psoriatic Arthritis Infliximab Biosimilar Switching

Biologic Response in PsA Block the Antibody Lupus, Myositis, Scleroderma Can GLP-1 Therapy Help PsA Beyond Losing Weight Can we do Pulmonary Testing at Home Fibromyalgia and Depression in Rheumatoid Arthritis Hydroxychloroquine Blood Levels and Retinopathy Risk JAK vs TNFi in RA Can Biomarkers Help us Choose Menopause in RA An Under Recognized Burden New Treatments in ILD Rosnilimab in RA Why May it be Relatively Safe Statins and eGFR in SLE Four Joint Fibromyalgia Warning

Day 2 of ACR Convergence 2026. Our expert faculty will highlight key abstracts, emerging research, and clinical insights from the day’s sessions, offering perspective on what these findings may mean for rheumatology practice. Drs. Adela Castro, Antoni Chan, Eric Dein Moderator: Dr. David Liew

Combination Therapy in Rheumatoid Arthritis Study Design and Comparative Effectiveness in RA Difficult to Treat RA What are our goals, really, in ILD New Treatments in Scleroderma Early Days A New Way to Measure Disease Activity in Rheumatoid Arthritis  

5mg kg HCQ Threshold in SLE Is it Time to Reconsider Does Scl-Ab change predict pulmonary decline in systemic sclerosis Does the Air we Breathe Shape Lupus Four Joint Fibromyalgia Warning Kidney Transplantation in Lupus Lupus Control without Steroid Burden Lupus Remission is not one Single Thing Mortality and Myositis in ILD Screen-detected ILD in Scleroderma Snippets & SNPs in ILD and Fibrosis When Low Cardiovascular Risk Misses Coronary Plaque

TNFi Failure in PsA to cycle or not cycle GLP-1 Drugs in Osteoarthritis and Rheumatoid Arthritis GLP-1s and Obesity in Rheumatic Disease Long-term Opioid Use in Lupus Does Obesity Play a Role TRIUMPH-4 Retatrutide GLP-1 in Osteoarthritis BE BOLD with Professor McInnes Can Tirzepatide Lower CV risk in Psoriasis and Psoriatic Arthritis

Join RheumNow for a live recap of Day 1 of ACR Convergence 2026. Our expert faculty will highlight key abstracts, emerging research, and clinical insights from the day’s sessions, offering perspective on what these findings may mean for rheumatology practice.

Dr. Jack Cush reviews the FDA approvals and news reports from this past week on RheumNow.com. This week we discuss playing the numbers in rheumatology, playing the long game with stem cell transplants, and a=the Positive spin on seronegative RA.

In Part 2 of our series on managing the complexities of PsA, Saakshi Khattri, MD, and Lindsay Tom, PA-C, discuss their experience individualizing treatment for real patients with multidomain PsA and the IL-23i and JAKi data that informed their decisions. Sponsored by AbbVie Medical Affairs + Health Impact. https://rheumnow.com/therapeutic-update/individualized-psa-treatment-il-23i-or-jaki